| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003004607A3 Aggrecanase molecules |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002098453A3 Orally administering parathyroid hormone and calcitonin |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002024909A3 Receptor nucleic acids and polypeptides |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | WO2002004003A3 Composition for the treatment of osteoarthritis |
| 07/31/2003 | WO2001034566A3 Protease inhibitors |
| 07/31/2003 | US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 07/31/2003 | US20030144510 Preparation of pharmaceutical salts |
| 07/31/2003 | US20030144507 Sulfonamide-containing heterocyclic compounds |
| 07/31/2003 | US20030144359 Dermatological use and a dermatological preparation |
| 07/31/2003 | US20030144347 Method for treating autoimmune disease |
| 07/31/2003 | US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals |
| 07/31/2003 | US20030144313 Non-steroidal, tetracylic compounds for estrogen-related treatments |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144309 Inhibitors of Src and other protein kinases |
| 07/31/2003 | US20030144302 Process for making substituted pyrazoles |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144292 Protease inhibitors such as N-((4'-Methoxy-(1,1'-biphenyl)-4-yl)-sulfonyl-N-methyl-amino)-(4 -hydroxycyclohexan-1-yl)-acetic acid for prophylaxis of neurodegenerative diseases, vision defects, skin disorders or as antiinflammatory agents |
| 07/31/2003 | US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis |
| 07/31/2003 | US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 07/31/2003 | US20030144233 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 07/31/2003 | US20030144209 Bone anabolic agents for the treatment of bone disease |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144197 Autologous growth factor cocktail composition, method of production and use |
| 07/31/2003 | US20030144187 Comprising an osteoprotegerin polypeptide and an immunoglobulin FC region; treatment of bone disorders |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143290 As anti-inflammatory and anti-arthritic agents |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143207 Remodeling of tissues and organ |
| 07/31/2003 | US20030143192 Chemokine beta-7 |
| 07/31/2003 | US20030143157 Method of treating tumors |
| 07/31/2003 | DE29824938U1 Pharmaceutical preparation comprising clodronate |
| 07/31/2003 | CA2511257A1 Stimulation of bone growth and cartilage formation with thrombin peptide derivatives |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473545A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2472835A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2472240A1 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen |
| 07/31/2003 | CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/30/2003 | EP1331224A1 Thiazole or oxazole derivatives |
| 07/30/2003 | EP1330535A2 Kini-3 motor protein and methods for its use |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330452A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 07/30/2003 | EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 07/30/2003 | EP1330447A2 Peptides as met-ap2 inhibitors |
| 07/30/2003 | EP1330439A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 07/30/2003 | EP1330430A2 Integrin receptor inhibitors |
| 07/30/2003 | EP1330270A2 Sustained release device for treating conditions of the joint |
| 07/30/2003 | EP1330268A1 Targeted therapeutic agents |
| 07/30/2003 | EP1330248A2 New treatments for restless legs syndrome |
| 07/30/2003 | EP1330239A2 Delayed and sustained release formulations and method of use thereof |
| 07/30/2003 | EP1330238A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 07/30/2003 | EP1187817B1 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same |
| 07/30/2003 | EP1171100B1 Solubilized pharmaceutical composition for parenteral administration |
| 07/30/2003 | EP1082962B1 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b |
| 07/30/2003 | EP1075256B1 Arylhydrocarbon receptor ligand antagonists |
| 07/30/2003 | EP0946541B1 Quinolines and their therapeutic use |
| 07/30/2003 | EP0831884B1 Use of bone morphogenic proteins for healing and repair of connective tissue attachment |
| 07/30/2003 | CN1433477A Method of achieving persistent transgene expression |
| 07/30/2003 | CN1433424A 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 07/30/2003 | CN1433416A N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433415A N-[5-[[[5-alkyl-2-oxazlyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433414A Benzazole derivatives and their use as JNK modulators |
| 07/30/2003 | CN1433412A Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 07/30/2003 | CN1433411A Chemical compounds |
| 07/30/2003 | CN1433408A Aminothiazole inhibitors of cyslin dependent kinases |
| 07/30/2003 | CN1433405A Quinazoline compounds |
| 07/30/2003 | CN1433396A Pharmaceutical compounds |
| 07/30/2003 | CN1432398A Chinese medicine prepn for treating femoral head necrosis |
| 07/30/2003 | CN1432392A Wind dispelling and pain relieving ointment |
| 07/30/2003 | CN1432389A Xuerongguyugao ointment for healing fracture and its prepn |
| 07/30/2003 | CN1432386A Bone setting pill |
| 07/30/2003 | CN1432384A Ointment for removing necrosis, promoting granulation and invigorating bone and its prepn |
| 07/30/2003 | CN1432383A New use of ledebouriella root |